This week has seen the launch of new and lower-priced biosimilars to AbbVie’s Humira (adalimumab), many months after Amgen’s Amjevita (adalimumab-atto) was released in the
Sandoz is a major player in biosimilar medicines, so it’s no surprise that it is concerned about how slowly these drugs are making inroads against their brand-name equival